NN-843
Alzheimer's Disease
Key Facts
About NanoNewron
NanoNewron is a private, preclinical-stage biotech based in San Diego, spun out from Rutgers University, with a mission to treat neurodegenerative diseases by enabling biologic delivery across the Blood-Brain Barrier. The company's patented NewroBus™ platform utilizes humanized camelid nanobodies that exploit Transferrin Receptor 1 (TfR1)-mediated transcytosis to shuttle therapeutic payloads into the brain. Its lead program, NN-843, targets Tumor Necrosis Factor-alpha (TNF-α) for Alzheimer's Disease, a pathway with strong scientific rationale but previously inaccessible to approved biologics. The company is led by an experienced team, including CEO Marco Taglietti, who has a track record of bringing drugs to market, and founder/CSO Dr. Luciano D'Adamio, a distinguished neuroscientist.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |